Edging Toward Interchangeability in Biosimilars
Executive Summary
An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.
You may also be interested in...
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.